Patient attrition between the emergency department and clinic among individuals presenting for HIV nonoccupational postexposure prophylaxis

Clinical Infectious Diseases

Volumn 58, Issue 11, 2014, Pages 1618-1624

  Bogoch, Isaac I ^a,c   Scully, Eileen P ^d,e   Zachary, Kimon C ^e   Yawetz, Sigal ^d,e   Mayer, Kenneth H ^e,f,g   Bell, Chaim M ^b,c   Andrews, Jason R ^e  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b Mt Sinai Hospital   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^g FENWAY INSTITUTE   (United States)

Author keywords

Care linkage; HIV; Postexposure prophylaxis; Prevention; Retention

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LOPINAVIR PLUS RITONAVIR;

ADULT; ARTICLE; EMERGENCY WARD; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RISK FACTOR; YOUNG ADULT; AMBULATORY CARE; COHORT ANALYSIS; EMERGENCY HEALTH SERVICE; HEALTH SERVICES RESEARCH; HIV INFECTIONS; PROCEDURES; PROSPECTIVE STUDY; UNITED STATES;

ADULT; AMBULATORY CARE; BOSTON; COHORT STUDIES; EMERGENCY MEDICAL SERVICES; FEMALE; HEALTH SERVICES RESEARCH; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; POST-EXPOSURE PROPHYLAXIS; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84900404631     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu118     Document Type: Article

References (23)

1. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med 1997; 337:1485-90.
2. Roland ME, Neilands TB, Krone MR, et al. Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis Off Publ Infect Dis Soc Am 2005; 41:1507-13.
3. Schechter M, do Lago RF, Mendelsohn AB, Moreira RI, Moulton LH, Harrison LH. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr 2004; 35:519-25.
4. Liu AY, Kittredge PV, Vittinghoff E, et al. Limited knowledge and use of HIV post-and pre-exposure prophylaxis among gay and bisexual men. J Acquir Immune Defic Syndr 2008; 47:241-7.
5. Mehta SA, Silvera R, Bernstein K, Holzman RS, Aberg JA, Daskalakis DC. Awareness of post-exposure HIV prophylaxis in high-risk men who have sex with men in New York City. Sex Transm Infect 2011; 87:344-8.
6. Rabaud C, Burty C, Grandidier M, et al. Tolerability of postexposure prophylaxis with the combination of zidovudine-lamivudine and lopinavir-ritonavir for HIV infection. Clin Infect Dis Off Publ Infect Dis Soc Am 2005; 40:303-5.
7. Mayer KH, Mimiaga MJ, Cohen D, et al. Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center. J Acquir Immune Defic Syndr 2008; 47:494-9.
8. Mayer KH, Mimiaga MJ, Gelman M, Grasso C. Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence. J Acquir Immune Defic Syndr 2012; 59:354-9.
9. Smith DK, Grohskopf LA, Black RJ, et al. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep 2005; 54:1-20.
10. Vittinghoff E, Glidden D, Shiboski S, McCulloch C. Regression methods in biostatistics. New York, NY: Springer, 2012.
11. Oldenburg CE, Burnighausen T, Harling G, Mimiaga MJ, Mayer KH. Adherence to post-exposure prophylaxis for non-forcible sexual exposure to HIV: a systematic reviewandmeta-analysis. Aids Behav 2014; 18:217-25.
12. Rothman RE, Kelen GD, Harvey L, et al. Factors associated with no or delayed linkage to care in newly diagnosed human immunodeficiency virus (HIV)-1-infected patients identified by emergency departmentbased rapid HIV screening programs in two urban EDs. Acad Emerg Med Off J Soc Acad Emerg Med 2012; 19:497-503.
13. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-99.
14. Liu AY, Vittinghoff E, Chillag K, et al. Sexual risk behavior among HIVuninfected men who have sex with men participating in a tenofovir preexposure prophylaxis randomized trial in the United States. J Acquir Immune Defic Syndr 2013; 64:87-94.
15. Carrieri MP, Patrizia CM, Bendiane MK, et al. Access to HIV prophylaxis for survivors of sexual assault: the tip of the iceberg. Antivir Ther 2006; 11:391-2.
16. Du Mont J, Myhr TL, Husson H, Macdonald S, Rachlis A, Loutfy MR. HIV postexposure prophylaxis use among Ontario female adolescent sexual assault victims: a prospective analysis. Sex Transm Dis 2008; 35:973-8.
17. Loutfy MR, Macdonald S, Myhr T, et al. Prospective cohort study of HIV post-exposure prophylaxis for sexual assault survivors. Antivir Ther 2008; 13:87-95.
18. Chacko L, Ford N, Sbaiti M, Siddiqui R. Adherence to HIV postexposure prophylaxis in victims of sexual assault: a systematic review and meta-analysis. Sex Transm Infect 2012; 88:335-41.
19. Abrahams N, Jewkes R, Lombard C, Mathews S, Campbell J, Meel B. Impact of telephonic psycho-social support on adherence to postexposure prophylaxis (PEP) after rape. Aids Care 2010; 22:1173-81.
20. Day S, Mears A, Bond K, Kulasegaram R. Post-exposure HIV prophylaxis following sexual exposure: a retrospective audit against recent draft BASHH guidance. Sex Transm Infect 2006; 82:236-7.
21. Shoptaw S, Rotheram-Fuller E, Landovitz RJ, et al. Non-occupational post exposure prophylaxis as a biobehavioral HIV-prevention intervention. Aids Care 2008; 20:376-81.
22. Tsai CC, Emau P, Follis KE, et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 1998; 72:4265-73.
23. Eron JJ Jr, Rockstroh JK, Reynes J, et al. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, activecontrolled, phase 3 non-inferiority trial. Lancet Infect Dis 2011; 11: 907-15.